The normal immune system contains T cells bearing antigen receptors which are not readily reactive to self. This invention describes a new method for activating self-reactive T cells in a peptide specific manner, a strategy designed to focus autoimmune cellular responses against cancers and persisting virus infections.
Enhancing T Cell Activation Using Altered MHC-Peptide LigandsTechnology #2010-271
Questions about this technology? Ask a Technology Manager